Glaxo: Disappointing results - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glaxo: Disappointing results

Feb 8, 2001

Glaxo has reported disappointing results for the year FY01 with the net profit falling 8.7% in the current year. A part of the reason is the trade boycotts of its products in some southern states, which reduced offtake by wholesalers and retailers. The company’s explanation for the boycott is that there was a change in the sales tax rates, which were passed on in the prices. The topline growth has been mainly a price led growth.

(Rs m) FY00 FY01 Change
Sales 8,855 9,346 5.5%
Other Income 309 316 2.2%
Expenditure 8,072 8,539 5.8%
Operating Profit (EBDIT) 783 808 3.1%
Operating Profit Margin (%) 8.8% 8.6%  
Interest 99 111  
Depreciation 162 164 1.2%
Profit before Tax 831 848 2.1%
Other Adjustments 219 235  
Tax 278 379 36.3%
Profit after Tax/(Loss) 772 705 -8.7%
Net profit margin (%) 8.7% 7.5%  
Earnings per share 12.91 11.78  

The results are also indicative of the tough domestic pharmaceutical environment and Glaxo has not been able to fulfill the promise (made after the first half results) that it would be able to outperform the industry.

The company is likely to announce the merger with SmithKline Pharma within the coming quarter. See Glaxo Smithkline merge. The stock is quoting at a price of Rs 434 which implies an earnings multiple of 34 times.

Equitymaster requests your view! Post a comment on "Glaxo: Disappointing results". Click here!

  

More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 3, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS